Literature DB >> 24662919

Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.

George L Mutter1, Nicolas M Monte2, Donna Neuberg2, Alex Ferenczy2, Charis Eng3.   

Abstract

Sporadic somatic inactivation of genes such as PTEN within histologically normal endometrium (latent precancers) is an early step in endometrial carcinogenesis. We have used clone-specific mutations of PTEN to determine the fate of latent precancers over time in women who do (high risk) and do not (low risk) develop endometrial neoplasia. PTEN immunohistochemistry was performed on 45 occurrences of endometrial neoplasia and their paired antecedent benign biopsies, along with age matched sample pairs from 167 patients who did not develop a neoplasm. When PTEN-deficient cells were present at both time points, DNA sequencing was performed to determine whether they were single or multiple independent events. Loss of PTEN protein in isolated glands was common in the initial normal biopsies of high- and low-risk groups (42% and 27%, respectively, P = 0.066). Protein-deficient glands have a tendency to disappear over time in low-risk women (P = 0.047) and, even when "persistent," are infrequently (19%, 3/16) confirmed to be the same clone. Similarly, only a small proportion (6.7%, 1/15) of latent precancers seen in high-risk women are the direct progenitors of subsequent neoplasia. There is a high rate of latent precancer turnover in both low- and high-risk patients, with rare long-term persistence of unique clones, which may or may not progress to a histologic lesion. The temporal dynamics of clonal emergence, persistence, and involution are sufficiently complex that in the individual patient, the presence of a latent precancer has an unknown contribution to long-term cancer risk. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662919      PMCID: PMC4058864          DOI: 10.1158/0008-5472.CAN-14-0108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Molecular identification of latent precancers in histologically normal endometrium.

Authors:  G L Mutter; T A Ince; J P Baak; G A Kust; X P Zhou; C Eng
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Involution of PTEN-null endometrial glands with progestin therapy.

Authors:  Wenxin Zheng; Heather E Baker; George L Mutter
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

3.  K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis.

Authors:  G L Mutter; H Wada; W C Faquin; T Enomoto
Journal:  Mol Pathol       Date:  1999-10

4.  Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues.

Authors:  W C Faquin; J T Fitzgerald; M C Lin; K A Boynton; M G Muto; G L Mutter
Journal:  Am J Clin Pathol       Date:  2000-04       Impact factor: 2.493

5.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

6.  Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas.

Authors:  W C Faquin; J T Fitzgerald; K A Boynton; G L Mutter
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

7.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.

Authors:  V Stambolic; M S Tsao; D Macpherson; A Suzuki; W B Chapman; T W Mak
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

8.  Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry.

Authors:  G L Mutter; J P Baak; C P Crum; R M Richart; A Ferenczy; W C Faquin
Journal:  J Pathol       Date:  2000-03       Impact factor: 7.996

Review 9.  Molecular pathology of endometrial carcinoma.

Authors:  Xavier Matias-Guiu; Jaime Prat
Journal:  Histopathology       Date:  2013-01       Impact factor: 5.087

Review 10.  Primary prevention of gynecologic cancers.

Authors:  D A Grimes; K E Economy
Journal:  Am J Obstet Gynecol       Date:  1995-01       Impact factor: 8.661

View more
  17 in total

1.  Significance of p53 expression in background endometrium in endometrial carcinoma.

Authors:  Thuy Thi Nguyen; Toru Hachisuga; Rie Urabe; Tomoko Kurita; Seiji Kagami; Toshinori Kawagoe; Shohei Shimajiri; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2015-03-19       Impact factor: 4.064

2.  Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.

Authors:  Serena Wong; Pei Hui; Natalia Buza
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

3.  Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.

Authors:  Hiroyasu Kashima; Ren-Chin Wu; Yihong Wang; Abdulrahman K Sinno; Tsutomu Miyamoto; Tanri Shiozawa; Tian-Li Wang; Amanda N Fader; Ie-Ming Shih
Journal:  Gynecol Oncol       Date:  2015-09-03       Impact factor: 5.482

Review 4.  Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.

Authors:  Paul J Yong; Aline Talhouk; Michael S Anglesio
Journal:  Reprod Sci       Date:  2021-01-19       Impact factor: 3.060

Review 5.  Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer.

Authors:  Suk-Young Lee
Journal:  Biomed Res Int       Date:  2021-05-05       Impact factor: 3.411

6.  Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Authors:  Anna Berg; Erling A Hoivik; Siv Mjøs; Frederik Holst; Henrica M J Werner; Ingvild L Tangen; Amaro Taylor-Weiner; William J Gibson; Kanthida Kusonmano; Elisabeth Wik; Jone Trovik; Mari K Halle; Anne M Øyan; Karl-Henning Kalland; Andrew D Cherniack; Rameen Beroukhim; Ingunn Stefansson; Gordon B Mills; Camilla Krakstad; Helga B Salvesen
Journal:  Oncotarget       Date:  2015-01-20

7.  Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.

Authors:  Xiaoping Ma; Yuzuo Hui; Li Lin; Yu Wu; Xian Zhang; Peishu Liu
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

8.  Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.

Authors:  Ayse Ayhan; Tsui-Lien Mao; Yohan Suryo Rahmanto; Felix Zeppernick; Hiroshi Ogawa; Ren-Chin Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol Clin Res       Date:  2015-05-27

Review 9.  Clinical actionability of molecular targets in endometrial cancer.

Authors:  Mary Ellen Urick; Daphne W Bell
Journal:  Nat Rev Cancer       Date:  2019-08-06       Impact factor: 60.716

10.  Characterizing the malignancy and drug resistance of cancer cells from their membrane resealing response.

Authors:  T H Hui; Z L Zhou; H W Fong; Roger K C Ngan; T Y Lee; Joseph S K Au; A H W Ngan; Timothy T C Yip; Y Lin
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.